| 05th week of 2021 patent applcation highlights part 11 |
| Patent application number | Title | Published |
|---|
| 20210030867 | ADJUVANT COMPOSITION CONTAINING ALUMINUM AND VACCINE COMPOSITION CONTAINING THE SAME - An adjuvant composition including a pH-sensitive carrier and an aluminum-containing substance is provided. An adjuvant that is highly safe and induces cell-mediated immunity effectively through cross-presentation is provided. | 2021-02-04 |
| 20210030868 | FORMULATION OF ANTIBODY BASED DRUGS FOR TREATING LUNG CANCER BY INHALATION - The present invention relates to formulations and method of drug administration useful for treating lung cancer (in particular, non-small lung cancer) by administering a therapeutic antibody drug with a soft mist inhaler or by nebulization. | 2021-02-04 |
| 20210030869 | DOSING REGIMEN FOR AN IDO INHIBITOR - The present disclosure relates to dosing regimens for treating cancer by administering epacadostat in combination with an antibody, or an antibody fragment thereof, that binds to PD-1. | 2021-02-04 |
| 20210030870 | MODULATION OF P62 AND STING ACTIVITY - The present invention relates to tools for modulating the P62-STING interaction as a method for modulating the innate immune response. The invention relates to compounds which are capable of either inhibiting or potentiating the interaction and thereby induce or prevent the innate immune response relating to STING. Specifically, compounds are provided for use in the treatment of disorders associated with STING activity, including cancer and immuno-deficient or auto-immune disorders. | 2021-02-04 |
| 20210030871 | LIQUID PHARMACEUTICAL COMPOSITION - The present invention relates to novel liquid pharmaceutical compositions of adalimumab, which include adalimumab or a biosimilar thereof, an acetate buffering agent/system such as sodium acetate/acetic acid, and a sugar stabiliser such as trehalose. Such a combination of components furnishes formulations having a stability (e.g. on storage and when exposed to stress) which is comparable to or an improvement upon those known in the art, and with fewer ingredients. Such advances will help adalimumab treatments to become more widely available at lower cost, and prolong the viability of pre-loaded delivery devices (e.g. pre-filled syringes) to reduce unnecessary waste of the drug. | 2021-02-04 |
| 20210030872 | METHOD AND COMPOSITION FOR TREATING CANCER OR SKIN LESION USING A VACCINE - A method for treating or reducing the incidence of recurrence of cancer, benign tumors, or HPV-associated lesions, including skin cancer, and particularly squamous cell carcinoma (SCC and basal-cell carcinoma, by administering one or more doses of HPV recombinant vaccine to a patient. | 2021-02-04 |
| 20210030873 | PHOTOSENSITIZER AND DERIVATIVES AND APPLICATION THEREOF - A photosensitizer and derivative, application thereof. The photosensitizer has the structure of general formula I, wherein X is S or Se, Y is organic or inorganic ion, R | 2021-02-04 |
| 20210030874 | Method of enhancing the antimicrobial action of systemically administered antibiotics - Antibiotic for use in a method comprising systemically administering a photosensitive antibiotic to a subject having a microbial infection in a target tissue to provide a blood plasma concentration of the antibiotic in the subject; allowing the plasma or tissue concentration of the antibiotic increase to a predetermined level; and subjecting the target tissue to photodynamic therapy in order to increase the antimicrobial action of the antibiotic in the target tissue. With light activation the efficacy of the photosensitizer antibiotic can be enhanced, the spectrum of the microbial effect broadened and even an antiviral effect can be obtained. Generally, the present invention can be exploited when there is a need for enhancement of the local antimicrobial effect of antibiotics. | 2021-02-04 |
| 20210030875 | MONOCLONAL ANTIBODY AND VACCINE TARGETING FILAMENTOUS BACTERIOPHAGE - Described here is a method for reducing or preventing | 2021-02-04 |
| 20210030876 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM - Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a T | 2021-02-04 |
| 20210030877 | Liquid Protein Formulations Containing Ionic Liquids - Concentrated, low-viscosity, low-volume liquid pharmaceutical formulations of proteins have been developed. Such formulations can be rapidly and conveniently administered by subcutaneous or intramuscular injection, rather than by lengthy intravenous infusion. These formulations include low-molecular-weight and/or high-molecular-weight proteins, such as mAbs, and viscosity-reducing ionic liquids. | 2021-02-04 |
| 20210030878 | NOVEL FORMULATION AND METHOD OF SYNTHESIS - The present invention provides a novel method for the preparation of | 2021-02-04 |
| 20210030879 | PRESSURE-SENSITIVE HYDROGEL AND METHOD OF USE - Embodiments of the disclosure may include a pressure sensitive hydrogel composition. The composition may include a liquid solvent, a polymer, and an acid gas. The composition may be capable of having a fluid phase in which the acid gas is dissolved in the solvent and the polymer is dissolved in the solvent, and the composition may be capable of having a gel phase in which the acid gas is not dissolved in the liquid solvent and the polymer is precipitated out of the solvent. The composition may also include a chemical compound or a pharmaceutical agent that can be released after the composition is delivered to a target tissue region. | 2021-02-04 |
| 20210030880 | CERAMIDE-LIKE LIPID-BASED DELIVERY VEHICLES AND USES THEREOF - Provided herein, in some aspects, are delivery vehicles comprising a ceramide and an agent to be delivered attached to the ceramide. In some embodiments, the ceramide does not comprise a fatty acid (i.e., is a sphingosine). In some embodiments, the ceramide comprises a fatty acid. In some embodiments, the ceramide is a glycoceramide. In some embodiments, the agent is attached to the ceramide covalently (e.g., via a linker). In some embodiments, the agent to be delivered is a therapeutic agent. The ceramide is able to deliver the agent to a cell or to a cellular compartment, as well as across the musical barrier. In some embodiments, agents delivered using the ceramide described herein exhibit longer half-life, compared to agents delivered alone. Methods of delivering a therapeutic agent to a subject for treating a disease using the ceramide delivery vehicle are also provided. | 2021-02-04 |
| 20210030881 | COMPOSITIONS AND METHODS FOR INCREASING EFFICIENCY OF CARDIAC METABOLISM - Compositions and methods for increasing efficiency of cardiac metabolism are provided. | 2021-02-04 |
| 20210030882 | USE OF BIS-IMINOBIOTIN COMPOUND FOR DRUG DELIVERY PURPOSES - A bis-iminobiotin compound which has a structure that enables the easy bonding of a bis-iminobiotin moiety to a drug or a fluorescent compound and is useful for the delivery of a drug to a streptavidin-labeled substance. The bis-iminobiotin compound is represented by general formula 9. In the formula, A, D and E independently represent a spacer capable of bonding two bicyclo rings to each other, wherein E represents a structure that may be branched, each of A, D and E may have a substituent, and A, D and E may together form a cyclic structure; J represents a functional group for achieving a click reaction; G represents a spacer capable of bonding E to J; and R represents a hydrogen atom, an acetyl group, a benzyl group, a trifluoroacetyl group or a Boc group. | 2021-02-04 |
| 20210030883 | COMPOSITIONS AND METHODS FOR TRANSPORT ACROSS THE BLOOD BRAIN BARRIER - Compositions and methods are provided including a transporter peptide derived from the loop2 domain of the neuronally-derived lynx1 protein which can be conjugated to an effector agent to form a transporter-effector complex for transport of the therapeutic effector agent to a target that is found across the blood brain barrier. | 2021-02-04 |
| 20210030884 | Novel Scaffolded HIV-1 Vaccine Immunogens - The present invention provides novel scaffolded HIV-1 vaccine immunogens. Some of the scaffolded immunogens contain a soluble gp140 trimer linked to the N-terminus of the nanoparticle subunit and a T-helper epitope that is fused via a short peptide spacer to the C-terminus of the nanoparticle subunit. Some other immunogens of the invention contain a soluble gp140 trimer protein that is linked to a stable nanoparticle via a short peptide spacer that is a T-helper epitope. Some of the scaffolded immunogens contain a gp140 trimer immunogen presented on a nanoparticle platform formed with I3-01 protein, E2p, or variants of protein 1VLW. Also provided in the invention are nucleic acids that encode the various vaccine immunogens described herein, and expression vectors and host cells harboring the nucleic acids. The invention further provides methods of using the scaffolded HIV-1 vaccine immunogens for preventing or treating HIV infections. | 2021-02-04 |
| 20210030885 | HUMANIZED ANTI-LIV1 ANTIBODIES FOR THE TREATMENT OF CANCER - Methods for using anti-LIV1 antibodies and antibody-drug conjugates, including anti-LIV1 antibody-drug conjugates, to inhibit proliferation of a cell, such as a LIV1-expressing cell, as well as for the treatment of cancers, such as, e.g., LIV1-associated solid tumors and breast cancer (e.g., locally advanced or metastatic breast cancer), are provided. | 2021-02-04 |
| 20210030886 | SULFAMIDE LINKER, CONJUGATES THEREOF, AND METHODS OF PREPARATION - The present invention relates to a compound comprising an alpha-end and an omega-end, the compound comprising on the alpha-end a reactive group Q | 2021-02-04 |
| 20210030887 | NON-NATURAL AMATOXIN-TYPE ANTIBODY CONJUGATE - Disclosed is a non-natural amatoxin-type antibody conjugate, said conjugate similar to the natural amatoxin is linked to a biopharmaceutically acceptable salt with a target biomolecule so as to obtain stability in blood plasma, and efficiently kill tumor cells in cells. | 2021-02-04 |
| 20210030888 | ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATES AND THEIR USE IN THE TREATMENT OF CANCER - The invention provides methods and compositions for treating cancer, such as colorectal cancer, non-small cell lung cancer, pancreatic cancer, head and neck cancer, bladder cancer, endometrial cancer, esophageal cancer and prostate cancer, in a subject, such as by the administration of antibody-drug conjugates that bind to tissue factor (TF). The invention also provides articles of manufacture and compositions comprising said antibody drug-conjugates that bind to TF for use in treating cancer (e.g., colorectal cancer, non-small cell lung cancer, pancreatic cancer, head and neck cancer, bladder cancer, endometrial cancer, esophageal cancer and prostate cancer). | 2021-02-04 |
| 20210030889 | VEGF ANTIBODY-DRUG CONJUGATES - A method of producing synergistic and enhanced efficacy in treating a disease in a subject includes providing an antibody, the antibody being a classic antibody or a modified biologic molecule that blocks a first target in the subject; providing a drug, the drug being a small molecule agent that blocks the first target or a second target in the subject; connecting the antibody and the drug with a linker to form an Antibody-Drug Synergism (ADS) compound; and treating the disease with the ADS compound. The linker is hydrolyzed in the subject over a certain time so that both the antibody and the drug exert their functions simultaneously, and the ADS compound confers better efficacy than either the antibody or the drug alone due to a synergism of the ADS compound. | 2021-02-04 |
| 20210030890 | HYDROGEL PRODRUG FOR TREATMENT - Aspects of the invention described herein include a hydrogel prodrug and methods of making a hydrogel prodrug for drug delivery. Also contemplated are methods of treating, inhibiting, ameliorating or inhibiting a disease or disorder. Without being limiting, the methods for treatment can be directed to a cancer, HIV, a virus, pain, a bacterial infection, a neurological disorder, hemorrhaging, multiple sclerosis, diabetes, high blood pressure, Alzheimer's, or inhibiting a fungal growth in a subject in need. | 2021-02-04 |
| 20210030891 | USE OF ALGINATE OLIGOMERS TO ENHANCE THE TRANSLOCATION OF MICRO/NANOPARTICLES ACROSS MUCUS LAYERS - A method for translocating a cationic micro/nanoparticle across a mucus layer, the method including (a) contacting the mucus layer with at least one alginate oligomer, the alginate oligomer having at least 70% mannuronate residues, together with the cationic micro/nanoparticle; or (b)(i) contacting the cationic micro/nanoparticle with an alginate oligomer having at least 70% mannuronate residues thereby forming a micro/nanoparticle carrying the alginate oligomer, and (b)(ii) contacting the mucus layer with the micro/nanoparticle prepared in step (b)(i). There is also provided a method for translocating a molecule of interest across a mucus layer including contacting the mucus layer with a micro/nanoparticle which is formed of self-assembling micro/nanoparticle forming components, wherein at least one is a cationic micro/nanoparticle forming agent and at least one is an alginate oligomer which has at least 70% mannuronate residues, and further comprises the molecule of interest, optionally wherein the molecule of interest is covalently bound to one or more of the self-assembling micro/nanoparticle forming components. | 2021-02-04 |
| 20210030892 | TREATMENT OF CELIAC DISEASE WITH TOLERIZING PARTICLES - The present disclosure relates to methods for treating Celiac Disease using tolerizing immune modifying particles that encapsulate antigenic material from the gliadin protein or other related proteins. | 2021-02-04 |
| 20210030893 | INHIBITING OR DOWNREGULATING GLYCOGEN SYNTHASE BY CREATING PREMATURE STOP CODONS USING ANTISENSE OLIGONUCLEOTIDES - The present disclosure relates to antisense oligonucleotides (AONs) for modulating the expression of glycogen synthase. AONs of the present disclosure may be useful in treating diseases associated with the modulation of the expression of the enzyme glycogen synthase, such as Pompe disease. Also provided by the present disclosure are compositions comprising AONs, as well as methods of down regulating mRNA coding for glycogen synthase, methods for reducing glycogen synthase in skeletal and cardiac muscle, and methods for treating Pompe disease. | 2021-02-04 |
| 20210030894 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DOMINANTLY-INHERITED CATECHOLAMINERGIC POLYMORPHIC VENTRICULAR TACHYCARDIA - Compositions and methods for the treatment of catecholaminergic polymorphic ventricular tachycardia (CPVT), particularly forms of the disease that are inherited in an autosomal dominant manner, by way of calsequestrin 2 (CASQ2) gene therapy can be used to treat CPVT caused by mutations in, for example, ryanodine receptor 2 and calmodulin, such as calmodulin 1 (CALM1) and CALM3. A variety of vectors are provided that can be used for the delivery of a CASQ2 transgene to a patient, such as a human patient suffering from autosomal dominant CPVT, including adeno-associated virus vectors, among others. | 2021-02-04 |
| 20210030895 | RESIN COMPOSITION AND MOLDED ARTICLE - The invention contains a resin and a near infrared fluorescent material which is one type or two or more types of compounds selected from General Formulas (I | 2021-02-04 |
| 20210030896 | BIO-ACTIVATED REPORTERS TO VISUALIZE, IN REAL TIME, SPECIFIC GENE THERAPY PRODUCTS - Provided herein are MRI contrast agents that are conditionally activated by an enzyme from a reporter gene coupled to a gene of interest. In some embodiments, provided herein is a platform where a substrate (blocking access of water to a Gd(III) ion) is removed by an enzyme that can be changed to accommodate a number of gene therapy targets. | 2021-02-04 |
| 20210030897 | BILIRUBIN DERIVATIVE-BASED DIAGNOSTIC AND THERAPEUTIC ULTRASOUND CONTRAST AGENT - Provided is a bilirubin derivative-based ultrasound contrast agent for diagnosis and treatment. The fine particles including the bilirubin derivative are sensitive to reactive oxygen species (ROS), bind with hydrophobic drugs, and can effectively chelate metals such as iron oxide nanoparticles. Therefore, the fine particle of the present invention can be used as an ultrasound contrast agent for diagnosis, as a magnetic resonance imaging contrast agent, or as a carrier for hydrophobic drugs or platinum-based drugs. | 2021-02-04 |
| 20210030898 | Thermally-Modulated Ultrasound Contrast Agents - The present disclosure relates to a novel nano-droplet composition comprising a fluorocarbon core and a polymeric shell, and the method of using and making the novel nano-droplet composition. The fluorocarbon core and the polymeric shell of the novel nano-droplet form a micelle with a size range of 10-1000 nm. The fluorocarbon core comprises at least one fluorocarbon compound with a formula of C | 2021-02-04 |
| 20210030899 | IMAGING HISTONE DEACETYLASES WITH A RADIOTRACER USING POSITRON EMISSION TOMOGRAPHY - Disclosed herein are histone deacetylase imaging agents for positron emission tomography and related imaging methods using the histone deacetylase imaging agents. The histone deacetylase imaging agents may be a compound of formula (I): | 2021-02-04 |
| 20210030900 | TARGETING COMPOUNDS AND METHODS FOR THEIR PRODUCTION - The present invention is directed to sarcophagine based compounds of formula (I). The compounds can complex a radioisotope, such as 64-copper and hence are useful in radioimaging and radiotherapy of cancers, e.g. colorectal cancer. The compounds work via a pre-targeting imaging approach in which the tetrazine reacts via click chemistry with a functional group such as a transcyclooctene which is pre-bound to a ligand such as a tumour specific antibody. | 2021-02-04 |
| 20210030901 | INORGANIC NANOCAGES, AND METHODS OF MAKING AND USING SAME - Provided are inorganic nanocages. The inorganic nanocages may be non-metal nanocages, transition metal oxide nanocages, or transition metal nanocages. Non-metal nanocages may include metal oxides. The inorganic nanocages can be made using micelles formed using pore expander molecules. The inorganic nanocages may be used as catalysts, drug delivery agents, diagnostic agents, therapeutic agents, and theranostic agents. | 2021-02-04 |
| 20210030902 | SYSTEMS AND METHODS FOR SANITIZING PORTABLE DEVICES - A sanitization device comprises an enclosure comprising emitters configured to emit sanitizing electro-optical radiation into an interior compartment. The sanitization device further includes a panel having an open configuration and a closed configuration adapted to enclose the inner compartment. The panel includes an inner surface forming a depression configured to receive a portable device when the panel is in the open configuration and to secure the portable device as the panel transitions to the closed configuration. The sanitization device may further comprise an actuator configured to transition the panel between the open and closed configurations in response to inputs received via a touchless input interface. | 2021-02-04 |
| 20210030903 | METHOD OF DECONTAMINATING A HYDROCARBON FLUID USING GAMMA RADIATION - In an aspect, a method of decontaminating a hydrocarbon fluid comprises irradiating the hydrocarbon fluid in a storage tank with a gamma radiation to maintain or reduce an amount of a microorganism in the storage tank; wherein a source of the gamma radiation is located within and/or proximal to the storage tank. In another aspect, a method of reducing an amount of a biocorrosion comprises irradiating the biocorrosion located on a surface of a device in contact with a hydrocarbon fluid with a gamma radiation; wherein a source of the gamma radiation is located within and/or proximal to the device. | 2021-02-04 |
| 20210030904 | SYSTEM AND METHOD FOR BACTERIA IRRADIATION FROM AN OCCUPANT ZONE OF A VEHICLE - A system for bacteria irradiation from an occupant zone of a vehicle is provided. The system comprises an interior portion disposed in the occupant zone. The interior portion has one of a predetermined surface porosity and a predetermined surface roughness. The interior portion has phosphorescent paint for visual indication. The system further comprises a high energy visible (HEV) light source integrated within the interior portion. The HEV light source has an emission wavelength of between about 375 nm and about 425 nm. The HEV light source further provides a cumulative energy of between about 1 J/cm | 2021-02-04 |
| 20210030905 | Multiple Light Emitter for Inactivating Microorganisms - Disclosed herein is a multiple light emitter device which inactivates microorganisms. The device includes at least two light emitters and at least one light-converting material arranged to convert at least a portion of light from the light emitters. Any unconverted light emitted from the light emitters and converted light emitted from the at least one light-converting material mixes to form a combined light, the combined light being white. In one aspect, the light emitters include at least one blue light emitter and at least one violet light emitter. In another aspect, the light emitters include one blue light emitter and one emitter within the range of approximately yellow to infrared light. | 2021-02-04 |
| 20210030906 | MICROBE INACTIVATION PROCESSING METHOD AND CELL ACTIVATION PROCESSING METHOD - Disclosed are a microbe inactivation processing method that can perform inactivation processing of microbes, while damage to human body cells is prevented or inhibited, with an efficient use of light emitted from a light source and the obtainment of a large effective irradiation area. Also provided are a cell activation processing method that can reliably activate target cells with high efficiency. The microbe inactivation processing method includes: a step of applying light emitted from a light source through an optical filter, with the light source configured to emit light having a wavelength within a wavelength range of 190 nm to 237 nm, in order to perform inactivation processing of a target microbe. When the light emitted from the light source is incident at an incident angle of 0°, the optical filter transmits at least a part of ultraviolet light having a wavelength within a range of not lower than 190 nm and not more than 230 nm, and transmits at least a part of ultraviolet light having a wavelength within a range of more than 230 nm and not more than 237 nm, and the optical filter blocks transmission of ultraviolet light having a wavelength out of a wavelength range of not lower than 190 nm and not more than 237 nm. | 2021-02-04 |
| 20210030907 | PLASMA TREATMENT DEVICE AND METHOD OF TREATING ITEMS - The use of plasma to clean or sterilize items can be particularly advantageous for items that cannot be readily washed or cleaned by standard methods. The toxicity and complications generating sufficient plasma makes it hard to use for such purposes. The subject invention addresses the problem by generating a minimal amount of highly reactive plasma to sterilize an item. This is achieved by reducing the amount of space and ambient air around and within the item. In this way, the plasma generated fills only the required volume of the item to be cleaned and the plasm is directed at the object, not directed at or released into non-target areas. | 2021-02-04 |
| 20210030908 | APPARATUS AND PROCESS FOR FOCUSED GAS PHASE APPLICATION OF BIOCIDE - The invention provides methods of oxidizing, sanitizing, disinfecting, and/or sterilizing a target. The method includes: ejecting a gas stream of a gaseous mixture comprising 50 to 30,000 ppm | 2021-02-04 |
| 20210030909 | SYSTEMS FOR MONITORING AND CONTROLLING DISINFECTION - A disinfection monitoring system, comprising: a sensor module configured to detect use of one or more disinfectants on a surface or in an area; a data logger module connected to the sensor module and configured to log data relating to detected uses of the one or more disinfectants; and a wireless communication module connected to the data logger module and configured to wirelessly communicate the logged data relating to detected use of the one or more disinfectants to a remote monitoring module. | 2021-02-04 |
| 20210030910 | ANTIMICROBIAL FRESHENING COMPOSITIONS - A fabric freshening product that includes (a) freshening aqueous liquid composition including a bispyridinium alkane antimicrobial active and a perfume, and (b) a spray device to produce a spray of the composition. | 2021-02-04 |
| 20210030911 | VISUAL AND OLFACTORY PRESENTATION DEVICE - A visual and olfactory presentation device combining a three-dimensional display card with one or more scented container attached thereto is provided. The visual and olfactory presentation device enables the synergetic effect of a visual presentation from an indicia area along the display card and an olfactory presentation from a scent formulation housed in each scented container. The scented container(s) may be disposed along the surface of the display card in such a way to enable a kickstand configuration along a supporting surface so that the indicia area is upwardly facing and enveloped in the scented formulation. | 2021-02-04 |
| 20210030912 | AEROSOL GENERATOR INCLUDING MULTI-COMPONENT WICK - An aerosol generator includes a composite conduit to transport multiple liquids to a heating element at flow rates such that the liquids arrive at the heating element in desirable concentrations. The heating element volatilizes the liquids to form volatilized fluid, which mixes with ambient air to form an aerosol with desirable concentrations of the multiple liquids. | 2021-02-04 |
| 20210030913 | DEVICE FOR DISPENSING A VOLATILE LIQUID - The present invention relates to a device for dispersing a volatile liquid comprising: a wick; a solid support; and a volatile liquid; wherein the wick is attached to the solid support; wherein the solid support is porous; and wherein the volatile liquid is contained within pores in the solid support. The invention also relates to methods of making such a device. | 2021-02-04 |
| 20210030914 | AIR PURIFIER AND AUTOMBILE AIR CONDITIONER WITH AIR PURIFIER - The disclosure is directed to an air purifier and an automobile air conditioner with an air purifier. The air purifier includes a reactor, a column, an air guider and a plurality of light emitting elements. The reactor includes an air inlet and an air outlet. The column is disposed in the reactor, and the column has a N-side walls. The air guider is disposed on the column, and the air guider is coated with a photocatalyst. The light emitting elements are placed on the N side walls of the column configured to irradiate on the photocatalyst, where each of the light emitting elements has an emitting angle of θ and θ*N>360°. | 2021-02-04 |
| 20210030915 | AIR PURIFICATION MODULE AND REFRIGERATOR COMPRISING THE SAME - An air purification module comprises: a housing having an interior space provided with an air inlet and an air outlet; an axial type blowing fan, mounted in the housing, for moving air from the air inlet to the air outlet; an air purifying unit, provided on a flow path of the air, for purifying the air; and a first guide for reducing the flow rate of the air between the blowing fan and the air purifying unit. The air purifying unit includes: a filter provided between the blowing fan and the air outlet; and a light source unit for providing light to the filter. | 2021-02-04 |
| 20210030916 | FLUID DISINFECTION DEVICE AND METHOD - A system for disinfecting a fluid containing contaminants (chemical and biological) includes a plurality of photocatalytic particles secured to a substrate which contacts the fluid to be disinfected. An agitator for imparting translation and/or vibrational movement is in operational communication with the substrate to increase the contact of photocatalytic particles with contaminants in the fluid. The system can include a source of photons having a wavelength corresponding to band gap energy of the photocatalytic particles to illuminate the substrate. Although the invention can be used to disinfect air in air supply registers of a heating, ventilating and air conditioning system, or in air ducts, the disinfection of any fluid (including water) is contemplated. | 2021-02-04 |
| 20210030917 | NANOFIBROUS ADHESION BARRIER - The present disclosure relates to adhesion barriers used in the biomedical field. Disclosed in particular is a nanofibrous mat suitable for use as an adhesion barrier in the biomedical field and obtained by the electrospinning method from a mixture of hyaluronic acid (HA) and sodium alginate (NaAlg) polymer solutions. | 2021-02-04 |
| 20210030918 | COATING OF FIBERS WITH DIPEPTIDE NANOSTRUCTURES USING ULTRASONIC CAVITATION - Provided herein are composite structures that include a core fiber and a plurality of peptide-based self-assembled nanostructures attached thereto, wherein the nanostructures may be loaded with a bioactive agent, such that the composite structures may act as slow-release drug-delivery medical device. Also provided is process for producing the composite structures, and uses thereof. | 2021-02-04 |
| 20210030919 | Medical hydrogel comprising nanofibrillar cellulose, tailored wound dressing, and methods for preparing thereof - A medical hydrogel includes nanofibrillar cellulose, wherein the content of nanofibrillar cellulose in the hydrogel is in the range of 1-3.5% (w/w), and the nanofibrillar cellulose includes anionic nanofibrillar cellulose having an average fibril diameter of 200 nm or less. The medical hydrogel can be used for inducing vascularization in wounds and/or for treating deep wounds of dermis and/or below tissue. | 2021-02-04 |
| 20210030920 | CHEMICALLY STRENGTHENED BIOACTIVE GLASS-CERAMICS - A chemically strengthened bioactive glass-ceramic composition as defined herein. Also disclosed are methods of making and using the disclosed compositions. | 2021-02-04 |
| 20210030921 | ZIRCONIUM AND TITANIUM PHOSPHATE COATINGS FOR IMPLANTS AND OTHER SUBSTRATES - This invention is directed to coated substrates, wherein the coating comprises titanium phosphate and/or zirconium phosphate. In certain embodiments the substrate is an implant for use in vivo. The invention is also directed to methods for forming coatings comprising or consisting of titanium phosphate and/or zirconium phosphate on the surface of a substrate. | 2021-02-04 |
| 20210030922 | CONFORMAL COATING OF CELLS FOR IMMUNOISOLATION - Hydrodynamic methods for conformally coating non-uniform size cells and cell clusters for implantation, thus preventing immune rejection or inflammation or autoimmune destruction while preserving cell functionality. A method for conformally coating cells and c clusters with hydrogels that are biocompatible, mechanically and chemically stable and porous, with an appropriate pore cut-off size. The methods of the invention are advantageously reproducible and result in a relatively high yield of coated versus non-coated cell clusters, without compromising cell functionality. Conformal coating devices configured to perform the methods of the invention, methods of optimally utilizing said devices and purifying the coated islets, and coated biomaterials made by said methods. | 2021-02-04 |
| 20210030923 | BIOLOGICAL VALVE MATERIAL, PREPARATION METHOD AND USE THEREOF, AND CROSS-LINKING AGENT AND USE THEREOF - The present application discloses a biological valve material which is a swim bladder derived biological valve material. The present application also discloses a method for preparing the biological valve material, includes: decellularizing a raw swim bladder; and cross-linking the decellularized swim bladder with a cross-linking agent. The present application also discloses use of the biological valve material, wherein the biological valve material is used for preparing one or more of a biological heart valve, a biological patch, and an artificial blood vessel. The present application also discloses a cross-linking agent for a bio-based material, including a cross-linking compound and an organic solvent. The cross-linking compound includes a polyphenol compound. The present application also discloses use of the cross-linking agent, wherein the cross-linking agent is used to cross-link the bio-based material after the decellularization treatment. | 2021-02-04 |
| 20210030924 | Tissue Engineered Intestine - The invention provides for engineered intestinal construct and methods of making these constructs. The invention also provides for methods of treating short bowel syndrome or methods of repairing an intestine after resection comprising inserting an engineered intestinal construct into the intestine of a subject in need. | 2021-02-04 |
| 20210030925 | VASCULAR REPAIR PATCH - A vascular repair patch comprises a polymeric substrate having first and second major surfaces, and at least first and second polymer filament layers, wherein the polymer filaments of the first polymer filament layer are oriented in parallel and the polymer filaments of the second polymer filament layer are oriented randomly. The patch may further include thrombogenic agents and/or extracellular matrix compounds to promote vascular tissue regeneration at the repair site. Further, included are methods of making and using the patch. | 2021-02-04 |
| 20210030926 | BIOINK COMPOSITION FOR DERMIS REGENERATION SHEET, METHOD FOR MANUFACTURING CUSTOMIZED DERMIS REGENERATION SHEET USING SAME, AND CUSTOMIZED DERMIS REGENERATION SHEET MANUFACTURED USING MANUFACTURING METHOD - The present invention relates to a bioink composition for a dermis regeneration sheet and a method for manufacturing a customized dermis regeneration sheet using same, the bioink composition comprising: a first liquid comprising an adipose tissue-derived stromal vascular fraction, an extracellular matrix, and fibrinogen; and a second liquid comprising thrombin. | 2021-02-04 |
| 20210030927 | SELF-EXPANDING DEVICES AND METHODS THEREFOR - Described here are delivery devices for delivering one or more implants to the body, and methods of using. The delivery devices may deliver implants to a variety of locations within the body, for a number of different uses. In some variations, the delivery devices have a cannula with one or more curved sections. In some variations, a pusher may be used to release one or more implants from the cannula. In some variations, one or more of the released implants may be a self-expanding device. Methods of delivering implants to one or more sinus cavities are also described here. | 2021-02-04 |
| 20210030928 | CROSS-LINKED FATTY ACID-BASED BIOMATERIALS - Fatty acid-based, pre-cure-derived biomaterials, methods of making the biomaterials, and methods of using them as drug delivery carriers are described. The fatty acid-derived biomaterials can be utilized alone or in combination with a medical device for the release and local delivery of one or more therapeutic agents. Methods of forming and tailoring the properties of said biomaterials and methods of using said biomaterials for treating injury in a mammal are also provided. | 2021-02-04 |
| 20210030929 | NANODIAMOND ELECTROSURGICAL COATING - A coating for an electrosurgical electrode to reduce the potential for sticking of tissue. The coating is an elastomer containing a plurality of diamond particles having an average diameter of between diameter of 0.5 and 500 nanometers and that comprise between 0.1 and 25 percent by weight of the coating. The coating may be formed by reducing a silicone dispersion with xylene, adding the plurality of diamond particles, and agglomerating the plurality of diamond particles through sonification and then applied to the device. The coasting may also be formed by reducing a silicone dispersion with xylene, adding the plurality of diamond particles, and agglomerating the plurality of diamond particles through sonification, and then applied to the device by plasma enhanced vapor deposition. | 2021-02-04 |
| 20210030930 | REDUCED PRESSURE THERAPY APPARATUS CONSTRUCTION AND CONTROL - Embodiments of a negative pressure wound therapy systems and methods for operating the systems are disclosed. In some embodiments, a system includes a pump assembly, canister, and a wound dressing configured to be positioned over a wound. The pump assembly, canister, and the wound dressing can be fluidically connected to facilitate delivery of negative pressure to a wound. The pump assembly can present graphical user interface screens for controlling and monitoring delivery of negative pressure. The system can be configured to efficiently deliver negative pressure and to detect and indicate presence of certain conditions, such as low pressure, high pressure, leak, canister full, and the like. Monitoring and detection of operating condition can be performed by measuring one or more operational parameters, such as pressure, flow rate, and the like. | 2021-02-04 |
| 20210030931 | DISPOSABLE PULSE LAVAGE/SUCTION DEVICES AND SYSTEMS FOR ORTHOPAEDIC SURGERY - The invention relates to disposable pulse lavage/suction devices ( | 2021-02-04 |
| 20210030932 | REDUCED PRESSURE THERAPY SYSTEMS AND METHODS INCLUDING AN ANTENNA - Embodiments of negative pressure wound therapy systems and methods are disclosed. In some embodiments, an apparatus includes a housing enclosing a source of negative pressure and a controller configured to operate the source of negative pressure to provide negative pressure wound therapy to a wound. The housing can also include a communications controller configured to wirelessly transmit and receive data using a communications antenna positioned on an antenna board. The antenna board can be mounted to a communications board that include the communications controller. The antenna board can be electrically connected to the communications board via a single connector on the communications board. The antenna's ground plane can be positioned on the communications board. | 2021-02-04 |
| 20210030933 | DEVICE FOR REMOVING BY SUCTION A BODILY FLUID, PRIMARILY NASAL FLUID - The invention relates to a device ( | 2021-02-04 |
| 20210030934 | MILK SUCTION AND COLLECTION DEVICE - Disclosed is a milk suction and collection device integrally manufactured and formed by silicone. The milk suction and collection device includes a main body which is hollow inside to define a milk storage chamber and is further provided with a milk pouring port operative to be selectively blocked. A breast protecting film is provided on a side in a thickness direction of the main body and is configured to be fitted with an outer periphery of a breast, and is further provided with a milk collecting port communicating with the milk storage chamber. The side of the main body of the milk suction and collection device provided with the breast protecting film is operative to be fitted with the breast because the milk suction and collection device is integrally manufactured and formed by silicone. When the milk pouring port is closed, a breast pumping function is achieved by squeezing the main body. When the milk pouring port is opened, a milk collecting function is achieved. | 2021-02-04 |
| 20210030935 | BLOOD PUMP HOUSING COMPONENT - Blood pump assemblies and methods of manufacturing and operating blood pump assemblies are provided. The blood pump assembly includes a pump and an impeller blade rotatably coupled to the pump. The blood pump assembly also includes a pump housing component sized for passage through a body lumen and coupled to the pump. The pump housing component includes a peripheral wall extending about a rotation axis of the impeller blade. The peripheral wall includes an inner peripheral wall surface and an outer peripheral wall surface. The peripheral wall also includes one or more blood exhaust apertures. Each blood exhaust aperture in the one or more blood exhaust apertures is defined by an inner aperture edge and an outer aperture edge. Each inner aperture edge is chamfered between the inner peripheral wall surface and the outer peripheral wall surface. | 2021-02-04 |
| 20210030936 | BLOOD PUMP SUPPORTED BY PASSIVE MAGNETIC FORCES - A blood pump may be provided that includes an inlet, an outlet and a rotor for delivering fluid from the inlet to the outlet, wherein the rotor is suspended within the blood pump by radial passive magnetic forces and axially is preloaded in one direction at least by way of passive magnetic forces so that, during a fluid-delivering rotation of the rotor, the axial thrust of the rotor acts counter to the magnetic attraction acting axially in the direction of the outlet. | 2021-02-04 |
| 20210030937 | MODULAR HEMODIALYSIS SYSTEM - Apparatuses, systems, and methods for the performance of kidney replacement therapy having or using a dialyzer, control components, sorbent cartridge, and fluid reservoirs configured to be of a weight and size suitable to be worn or carried by an individual requiring treatment are disclosed. The system has a controlled compliance dialysis circuit, where a control pump controls the bi-directional movement of fluid across a dialysis membrane. A first sorbent cartridge is provided for use in a portable treatment module having activated carbon and zirconium oxide. The system also provides for the monitoring of an inlet and outlet conductivity of a sorbent cartridge containing urease to provide a facility to quantify or monitor the removal of urea by a detachable urea removal module. | 2021-02-04 |
| 20210030938 | A BLOOD HOSE SET, A CONTROL DEVICE OR CLOSED-LOOP CONTROL DEVICE, A BLOOD TREATMENT APPARATUS AND A METHOD FOR THE SINGLE-NEEDLE TREATMENT - The present disclosure relates to a blood hose set, or to an extracorporeal blood circuit, for a single-needle treatment. In some embodiments, the set includes: a patient hose line and a Y-shaped connector or three-way connecter, which is connected to the patient hose line.In some embodiments, the blood hose set does not include any single-needle chamber in a blood path or on a blood side, nor is it connected to any single-needle chamber provided in a blood path or on a blood side. The present disclosure further relates to a control device or closed-loop control device, a blood treatment apparatus, a method for the single-needle treatment, a digital storage medium, a computer program product and a computer program. | 2021-02-04 |
| 20210030939 | Therapy Control by Comprehensive Feedback - The application refers to a medical treatment device a medical treatment system and a method for operating the medical treatment device and medical treatment system for treatment of a patient, comprising a sensor interface for receiving sensor data from a plurality of different external and internal peripheral sensors, a controller for processing the received sensor data in order to calculate control data and for providing the calculated control data for controlling medical treatment-related devices or for controlling a configuration of medical treatment-related apparatuses and an output interface for providing the control data. | 2021-02-04 |
| 20210030940 | Membrane Oxygenator with Gas Exchange Fiber Lumen Access Based on Fiber Effective Length - Membrane oxygenators useful in a variety of medical situations, including various short-term procedures and relatively longer-term life support, and components of membrane-based oxygenators, such as conditioning modules for exchanging oxygen for carbon dioxide during extracorporeal conditioning of blood, are described. A conditioning module includes a plurality of mats of hollow fibers and a potting material disposed throughout the peripheral edges of the mats to create a circumferential seal that defines a passageway through the plurality of fiber mats having a substantially circular cross-sectional shape. The circumferential seal defines an effective fiber length for each of the hollow fibers. A resisting member is disposed across the proximal ends of at least some of the hollow fibers and is adapted to resist fluid flow into each of the hollow fibers based on the effective fiber length of the particular hollow fiber. | 2021-02-04 |
| 20210030941 | DEVICE FOR THE SELECTIVE REMOVAL OF MOLECULES FROM TISSUES OR FLUIDS - An implantable device is for the selective removal of molecules from tissues or fluids so as to allow the selective removal of a particular molecule of interest (target molecule) from any type of fluid solution or tissue, including biological tissues or fluids. The device operates through the complementary action of specific-binding molecules (antibodies) directed against the target molecule inside the device. The device includes a nanoperforated membrane having pores larger than the target molecule but smaller than the antibodies, such that the fluid can be removed through a second catheter with a lower concentration of target molecules. | 2021-02-04 |
| 20210030942 | DEVICES, SYSTEMS AND METHODS FOR THE BROAD-SPECTRUM REDUCTION OF PRO-INFLAMMATORY CYTOKINES IN BLOOD - Devices, systems and methods for the broad-spectrum reduction of pro-inflammatory cytokines in blood. The pro-inflammatory cytokines can be freely circulating in the blood as well as cytokines that are transported within or bound to the surface of particles collectively referred to as CytoVesicles while simultaneously adsorbing toxins and pathogens from blood and blood plasma. A plasma separation column with binding, capture and adsorbent components optimize the removal of cytokines and CytoVesicles from blood while minimizing the removal of essential blood elements. Adsorbent components are incorporated within the extra-lumen space, outside of the plasma fiber walls and within the outer shell of the column and can include activated carbon, ion exchange resins and non-ionic exchange resins. The resulting devices, systems and methods alleviate the symptoms or severity of a wide range of disease conditions associated with an abnormal production or dysregulation of pro-inflammatory cytokines. | 2021-02-04 |
| 20210030943 | Combined Bio-Artificial Liver Support System - A combined bio-artificial liver support system, includes branch tubes that are connected in sequence: a blood input branch tube, an upstream tail end, a first plasma separation branch tube comprising at least a first plasma separator, a non-biological purification branch tube comprising at least a plasma perfusion device and a bilirubin adsorber, a biological purification branch tube comprising at least a hepatocyte culture cartridge assembly, and a plasma return branch tube, a downstream tail end of which is set as a blood output end. | 2021-02-04 |
| 20210030944 | Apparatus And Method For Securing An Elongate Member To A Medical Instrument - An apparatus and method of securing an elongate member to a medical instrument. The apparatus comprising an attachment device including a base, a liner, and an adhesive. The base comprising an aperture configured to receive the elongate member, wherein the liner may be positioned adjacent the aperture and axially aligned with the elongate member when the attachment device is coupled to the medical instrument. The attachment device may comprise a pair of apertures and the liner may be positioned adjacent the adhesive and at least partially between the pair of apertures. The method of securing the elongate member to the medical instrument comprises threading the elongate member through the aperture of the attachment device and adhering the attachment device to the medical instrument. The method of manufacturing the attachment device may comprise cutting the aperture in the base, the adhesive, and liner. | 2021-02-04 |
| 20210030945 | MEDICAL DEVICE PACKAGING AND RELATED METHODS - According to one aspect of the disclosure, packaging for a sterile syringe having a nominal size of less than 1 mL may include a flexible tray having a cavity for containing the syringe. The cavity may include an opening, one or more sidewalls, and a base. A lip may surround the opening, may extend radially outward from the cavity, and may define a periphery of the tray. A removable cover may have a periphery that is adhered to the lip, and the removable cover may be permeable to a gaseous sterilant, including one or more of vaporized hydrogen peroxide or ethylene oxide. A projection may be associated with the base of the cavity and may extend away from the base of the cavity in a direction opposite to the opening of the cavity. | 2021-02-04 |
| 20210030946 | MEDICAL APPARATUS AND METHOD FOR STERILIZING MEDICAL APPARATUS - According to the invention, there is provided a medical apparatus including: one or more sterile pre-filled syringe; one or more first protective container including the one or more sterile prefilled syringe, wherein the one or more first protective container is impermeable to moisture and/or sterilizing agents; a second protective container including one or more medical components and the one or more first protective container; and a package impermeable to bacteria including the second protective container. | 2021-02-04 |
| 20210030947 | AMBULATORY DEVICE AND COMPONENTS THEREOF - Certain embodiments provide multi-medicament or single medicament infusion systems for preventing the cross-channeling or improper delivery of medicaments. The system may include one or more of an infusion pump, medicament cartridges, cartridge connectors, a multi-channel fluid conduit, and an infusion set. The medicament cartridges may be sized and shaped differently such that the medicament reservoirs can only be inserted into the pump under selected configurations. | 2021-02-04 |
| 20210030948 | SYRINGE PUMP WITH FLANGE CLAMP SENSOR - Syringe pumps are described herein. A syringe pump is disclosed comprising a syringe pump body, a flange clamp and a sensing switch. The syringe pump body defining a syringe body recess and a syringe plunger recess, wherein the syringe body recess and the syringe plunger recess are configured to cooperatively receive a syringe. The flange clamp is coupled to a mating surface of the syringe pump body disposed between the syringe body recess and the syringe plunger recess, wherein the flange clamp is configured to be spaced apart from the mating surface to receive a syringe flange of the syringe. The sensing switch extends through the mating surface, wherein the sensing switch is configured to be in a closed state when the flange clamp is in contact with the sensing switch and in an open state when the flange clamp is spaced apart from the sensing switch. | 2021-02-04 |
| 20210030949 | AMBULATORY DEVICE AND COMPONENTS THEREOF - Certain embodiments provide multi-medicament or single medicament infusion systems for preventing the cross-channeling or improper delivery of medicaments. The system may include one or more of an infusion pump, medicament cartridges, cartridge connectors, a multi-channel fluid conduit, and an infusion set. The medicament cartridges may be sized and shaped differently such that the medicament reservoirs can only be inserted into the pump under selected configurations. | 2021-02-04 |
| 20210030950 | SYRINGE ROLLING APPARATUS AND METHOD - A syringe rolling apparatus for initial rolling of a rolling diaphragm syringe from an unrolled state to a rolled state has a pressure jacket configured for receiving an empty, unrolled rolling diaphragm syringe, a piston reciprocally movable within the pressure jacket and configured for contacting an end wall of the syringe rolling diaphragm syringe to initiate a rolling of a flexible sidewall of the rolling diaphragm syringe, and a seal assembly configured for engaging an open discharge neck of the rolling diaphragm syringe. The seal assembly is in fluid communication with a source of pressurized fluid to pressurize an interior of the rolling diaphragm syringe during a distal movement of the piston. A method for initial rolling of a rolling diaphragm syringe from an unrolled state to a rolled state is also disclosed. | 2021-02-04 |
| 20210030951 | Infusion Set Having Reduced Patient Pain - A painless infusion set has an affixed portion and may have a disposable or reusable insertion device portion. The infusion set or its inserter may have methods or mechanisms to utilize gas, liquid, gel, or solid within phase or through phase change with user-controlled variably slow insertion to reduce pain. In one example, a canister of a pain reducing material is in the insertion device. The pain reducing material can be dispensed onto the skin before, during, or after insertion of the needle or cannula to reduce pain. | 2021-02-04 |
| 20210030952 | DEVICES AND METHODS FOR FLOW RESTRICTION IN A MICROFLUIDIC CIRCUIT FOR DRUG DELIVERY - A device for administering a liquid drug formulation to a patient is disclosed. The device includes a reservoir configured to hold a quantity of a liquid drug formulation and a microfluidic circuit that includes at least one flow path configured to transport the liquid drug formulation from the reservoir to a drug release outlet. The microfluidic circuit includes at least one flow restrictor in the at least one flow path. The at least one flow restrictor includes a first substrate secured to a second substrate with a flow channel formed into at least one of the first substrate and the second substrate, and disposed between the first substrate and the second substrate. | 2021-02-04 |
| 20210030953 | SYSTEMS, APPARATUSES AND METHODS FOR OCCLUSION DETECTION USING PUMP OPERATION MEASUREMENT - A technical solution for monitoring operation of a medical delivery device such as an infusion pump for occlusion is provided that employs sensing pump motor current and monitoring average motor current difference as between dispense and aspirate strokes in a pump cycle. The solution can be implemented alone or in combination with other occlusion sensing methods that use one or more of pump measurement data such as pump stroke duration (e.g., duration of aspirate stroke or dispense stroke in a rotational metering-type pump or a reciprocating-type pump), end-stop or limit switch activation, and duration difference between aspirate and dispense strokes to detect occlusion. | 2021-02-04 |
| 20210030954 | RESERVOIR FOR COLLECTION AND REUSE OF DIVERTED MEDIUM - A system allows for collection and re-use of a fluid medium derived from diverting at least some of the fluid medium of an injection. The system comprises a sterile container, an injector, a delivery catheter, a flow diverter assembly and a diversion reservoir assembly. The delivery catheter is in communication with a selected site within a patient's body. The flow diverter assembly is disposed in a flow path between the injector and the delivery catheter and is configured to divert at least a portion of a medium of the injection from the flow path. The diversion reservoir assembly has a reservoir chamber fluidly coupled to the flow diverter assembly. The reservoir chamber is configured to receive the diverted portion of the fluid medium to allow re-use by the medium injector of the diverted portion. | 2021-02-04 |
| 20210030955 | ADJUSTING INSULIN DELIVERY RATES - A method may include displaying to a user an interface at which the user inputs a fear of hypoglycemia index (FHI), the FHI corresponding to an acceptable probability of a blood glucose level being below a threshold blood glucose level. The method may also include receiving blood glucose data for a person with diabetes (PWD). The method may additionally include calculating a probability of the PWD having a blood glucose level below the threshold blood glucose level based on the variability of the received blood glucose data. The method may also include setting one or more target blood glucose levels to align the probability of the PWD having a blood glucose level below the threshold blood glucose level with the acceptable probability associated with the user input FHI. The method may additionally include delivering insulin, using the insulin delivery device, based on the target blood glucose level. | 2021-02-04 |
| 20210030956 | INTEGRATED INSULIN DELIVERY SYSTEM WITH CONTINUOUS GLUCOSE SENSOR - Systems and methods for integrating a continuous glucose sensor | 2021-02-04 |
| 20210030957 | DUAL FLUID INJECTION SYSTEM - A dual fluid injection device is provided that includes at least two syringes. A hub is provided, to which a first syringe and a second syringe are simultaneously connected. The hub includes a fluid delivery member at an end thereof for injection at a site. The first syringe and the second syringe are actuated independently at a directional control valve. | 2021-02-04 |
| 20210030958 | Fluid Responsive Devices and Methods - Aspects provide fluid responsive actuators and methods of using fluid responsive actuators capable of generating a power-to-volume ratio sufficient to inject a drug from a syringe within an injection period from about 1 to about 60 seconds after exposure of the fluid responsive elements to a fluid. The fluid responsive actuators can be used to inject viscous drugs to a patient. | 2021-02-04 |
| 20210030959 | INSERTION DEVICE FOR A BIOSENSOR AND INSERTION METHOD THEREOF - An insertion device includes a cover body, an insertion module. The insertion module is disposed in the cover body, and includes a main body, an insertion seat, a first elastic member, a retraction seat and a second elastic member. When the cover body is depressed, the insertion seat is driven by the first elastic member to perform an automatic-insertion operation and to collapse a limiting structure between the insertion seat and the cover body. A limiting structure between the insertion seat and the retraction seat collapses upon the collapse of the limiting structure between the insertion seat and the cover body, so that the retraction seat is driven by the second elastic member to perform an automatic-retraction operation. | 2021-02-04 |
| 20210030960 | INSERTION DEVICE FOR A BIOSENSOR AND INSERTION METHOD THEREOF - An insertion device includes an upper casing, an insertion module and a lower casing. The insertion module is disposed in the upper casing, and includes a main body assembly, an insertion seat, a first elastic member, a retraction seat and a second elastic member. When the upper casing is depressed, the insertion seat is driven by the first elastic member to perform an automatic-insertion operation, such that limiting structure between the insertion seat and the retraction seat collapses upon the collapse of another limiting structure between the insertion seat and the main body assembly, and that the retraction seat is driven by the second elastic member to perform an automatic-retraction operation. | 2021-02-04 |
| 20210030961 | INSERTION DEVICE FOR A BIOSENSOR AND INSERTION METHOD THEREOF - An insertion device includes a cover body and an insertion module. The insertion module is disposed in the cover body, and includes a main body, an insertion seat, a pre-compressed first elastic member, a retraction seat and a pre-compressed second elastic member. The restoring force of the pre-compressed first elastic member is configured not to act on the cover body during depression of the cover body. | 2021-02-04 |
| 20210030962 | Auto Injector With Improved Functionality - The invention relates to an auto injector, by which a fixed dose of a medicament can be injected as self-treatment, and by which needle exposure to an accessible position, injection of the medicament and retraction of the needle to an inaccessible position is automatically performed as a continuous sequence, after the auto injector is triggered. The invention provides solutions to improve the functionality of the retraction of the needle and the general experience of the use. | 2021-02-04 |
| 20210030963 | Drug Delivery Device - A drug delivery device comprises a housing adapted to receive a primary package, the housing comprising a distal surface adapted to be placed against an injection site and a proximal surface opposite the distal surface, the proximal surface adapted to be held in the palm of a user's hand during drug delivery, the housing having a flat form-factor in such a manner that a first extension of the housing between the distal surface and the proximal surface is less than at least one extension at right angles to the first extension. | 2021-02-04 |
| 20210030964 | CONTAINERS HAVING CLOSED ENDS, CONTAINER ASSEMBLIES AND MEDICAL DEVICES HAVING SUCH CONTAINERS - Container assemblies for accommodating pharmaceutical compositions are provided. The container assembly includes a container and a plunger. The container has a hollow cylindrical body with an open end and a closed end, which is closed by a bottom portion. The hollow cylindrical body has a length (L), an outer diameter (DO), and an inner diameter with a length to outer diameter ratio between 3:1 and 15:1. The hollow cylindrical body and the bottom portion are formed integrally and of the same material, which is a glass or polymer material. The container has an inner surface with an average Zn-leachability of 0.00085 μg/cm | 2021-02-04 |
| 20210030965 | SINGLE USE DELIVERY DEVICE - The invention is a single use delivery device configured to enable reconstitution of a lyophilized agent (e.g., vaccine, drug, medicament, etc.) stored within for subsequent delivery of the reconstituted fluid agent to a patient in a controlled manner and without requiring specialized skill in reconstituting the agent or administering delivery of such agent. The delivery device is prefilled with an individual dose of a lyophilized agent and configured to be filled on-site and in the field with a dose of diluent for reconstitution of the lyophilized agent, while remaining sterile and preventing the potential for contamination during the filling process. The delivery device is further configured to be rendered incapable of reuse followings its intended use of delivering the fluid agent to a patient, thereby preventing reuse of the device and reducing the risk of the spreading blood-borne diseases through reuse. | 2021-02-04 |
| 20210030966 | Flow Communication Unit With Unconnected and Connected Configuration - A flow communication unit ( | 2021-02-04 |
